MyoKardia, Inc. (MYOK) Holdings Boosted by Northern Trust Corp

Northern Trust Corp raised its position in MyoKardia, Inc. (NASDAQ:MYOK) by 31.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 202,983 shares of the biotechnology company’s stock after buying an additional 49,044 shares during the quarter. Northern Trust Corp owned about 0.65% of MyoKardia worth $2,658,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Nationwide Fund Advisors grew its holdings in shares of MyoKardia by 36.3% during the 2nd quarter. Nationwide Fund Advisors now owns 9,729 shares of the biotechnology company’s stock valued at $127,000 after purchasing an additional 2,591 shares during the last quarter. Alliancebernstein L.P. bought a new stake in shares of MyoKardia during the 2nd quarter valued at approximately $148,000. State of Wisconsin Investment Board bought a new stake in shares of MyoKardia during the 2nd quarter valued at approximately $157,000. Rhumbline Advisers grew its holdings in shares of MyoKardia by 45.4% during the 2nd quarter. Rhumbline Advisers now owns 18,489 shares of the biotechnology company’s stock valued at $242,000 after purchasing an additional 5,773 shares during the last quarter. Finally, Wells Fargo & Company MN grew its holdings in shares of MyoKardia by 2.5% during the 2nd quarter. Wells Fargo & Company MN now owns 18,539 shares of the biotechnology company’s stock valued at $243,000 after purchasing an additional 455 shares during the last quarter. 44.93% of the stock is currently owned by hedge funds and other institutional investors.

Several equities research analysts recently issued reports on MYOK shares. BidaskClub raised shares of MyoKardia from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 5th. Zacks Investment Research lowered shares of MyoKardia from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. BMO Capital Markets reaffirmed an “outperform” rating and set a $65.00 price target (up from $45.00) on shares of MyoKardia in a report on Monday, August 21st. Cowen Inc lifted their price target on shares of MyoKardia from $28.00 to $56.00 and gave the company an “outperform” rating in a report on Monday, August 7th. Finally, Wells Fargo & Company reaffirmed an “outperform” rating and set a $48.00 price target (up from $31.00) on shares of MyoKardia in a report on Monday, August 7th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $55.00.

In related news, Director Kevin P. Starr sold 75,313 shares of MyoKardia stock in a transaction that occurred on Tuesday, October 3rd. The shares were sold at an average price of $40.28, for a total transaction of $3,033,607.64. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Anastasios Gianakakos sold 4,300 shares of MyoKardia stock in a transaction that occurred on Monday, November 6th. The stock was sold at an average price of $40.23, for a total transaction of $172,989.00. Following the sale, the chief executive officer now owns 513,417 shares in the company, valued at $20,654,765.91. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,713,513 shares of company stock worth $72,678,568. 33.40% of the stock is owned by corporate insiders.

Shares of MyoKardia, Inc. (NASDAQ:MYOK) opened at $35.25 on Monday. MyoKardia, Inc. has a 1 year low of $10.55 and a 1 year high of $49.55.

MyoKardia (NASDAQ:MYOK) last posted its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.42) EPS for the quarter, hitting the consensus estimate of ($0.42). MyoKardia had a negative net margin of 53.49% and a negative return on equity of 14.92%. The business had revenue of $5.63 million for the quarter, compared to the consensus estimate of $6.10 million. During the same period last year, the company earned ($0.35) EPS. The firm’s revenue was up 58.6% compared to the same quarter last year. equities analysts predict that MyoKardia, Inc. will post -1.62 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Transcript Daily and is the property of of Transcript Daily. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be read at https://transcriptdaily.com/2017/11/27/myokardia-inc-myok-holdings-boosted-by-northern-trust-corp.html.

About MyoKardia

MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.

Institutional Ownership by Quarter for MyoKardia (NASDAQ:MYOK)

Receive News & Ratings for MyoKardia Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MyoKardia Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply